PE20160173A1 - SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD ANTAGONISTA DE RECEPTORES MUSCARINICOS ASI COMO ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENERGICO - Google Patents

SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD ANTAGONISTA DE RECEPTORES MUSCARINICOS ASI COMO ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENERGICO

Info

Publication number
PE20160173A1
PE20160173A1 PE2016000066A PE2016000066A PE20160173A1 PE 20160173 A1 PE20160173 A1 PE 20160173A1 PE 2016000066 A PE2016000066 A PE 2016000066A PE 2016000066 A PE2016000066 A PE 2016000066A PE 20160173 A1 PE20160173 A1 PE 20160173A1
Authority
PE
Peru
Prior art keywords
amino
hydroxy
hydroxyquinolin
methyl
hydroxyethyl
Prior art date
Application number
PE2016000066A
Other languages
English (en)
Spanish (es)
Inventor
Carrera Francesc Carrera
Jane Montserrat Julia
Duran Carlos Puig
Andres Juan Antonio Perez
Quinones Maria Prat
Lorenzo Francesca Pajuelo
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48917474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160173(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of PE20160173A1 publication Critical patent/PE20160173A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/15Fumaric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PE2016000066A 2013-07-25 2014-07-24 SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD ANTAGONISTA DE RECEPTORES MUSCARINICOS ASI COMO ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENERGICO PE20160173A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13382304 2013-07-25

Publications (1)

Publication Number Publication Date
PE20160173A1 true PE20160173A1 (es) 2016-04-13

Family

ID=48917474

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000066A PE20160173A1 (es) 2013-07-25 2014-07-24 SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD ANTAGONISTA DE RECEPTORES MUSCARINICOS ASI COMO ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENERGICO

Country Status (36)

Country Link
US (1) US9579316B2 (enExample)
EP (1) EP3024489B1 (enExample)
JP (1) JP6374962B2 (enExample)
KR (1) KR102338155B1 (enExample)
CN (2) CN105492027A (enExample)
AR (1) AR097079A1 (enExample)
AU (1) AU2014295028B2 (enExample)
BR (1) BR112016001295B1 (enExample)
CA (1) CA2917596C (enExample)
CL (1) CL2016000187A1 (enExample)
CR (1) CR20160043A (enExample)
CY (1) CY1122920T1 (enExample)
DK (1) DK3024489T3 (enExample)
DO (1) DOP2016000011A (enExample)
EA (1) EA035436B1 (enExample)
ES (1) ES2788627T3 (enExample)
HR (1) HRP20200670T1 (enExample)
HU (1) HUE049441T2 (enExample)
IL (1) IL243173B (enExample)
LT (1) LT3024489T (enExample)
MX (1) MX360837B (enExample)
MY (1) MY184681A (enExample)
NI (1) NI201600012A (enExample)
NZ (1) NZ715128A (enExample)
PE (1) PE20160173A1 (enExample)
PH (1) PH12016500125A1 (enExample)
PL (1) PL3024489T3 (enExample)
PT (1) PT3024489T (enExample)
RS (1) RS60185B1 (enExample)
SG (1) SG11201510682YA (enExample)
SI (1) SI3024489T1 (enExample)
SM (1) SMT202000185T1 (enExample)
TW (1) TWI641373B (enExample)
UY (1) UY35678A (enExample)
WO (1) WO2015011244A1 (enExample)
ZA (1) ZA201509203B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
AU2013360866A1 (en) 2012-12-18 2015-07-02 Almirall, S.A. New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activity
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
HK1218855A1 (zh) 2013-04-30 2017-03-17 Otitopic Inc. 干粉製劑及使用方法
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β2腎上腺素受體促效劑二者之活性的2-胺基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有maba化合物和皮質類固醇之組合
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β2腎上腺素促效劑及M3蕈毒拮抗劑活性之新穎雙環衍生物
US20190185461A1 (en) * 2015-07-21 2019-06-20 Sichuan Haisco Pharmaceutical Co., Ltd. Benzocyclic derivative having b2-receptor agonist activity and m3-receptor antagonist activity and medical use thereof
CN106554350B (zh) * 2015-09-29 2019-12-20 四川海思科制药有限公司 具有β2激动活性的苯并杂环衍生物及其制法和应用
TW201835041A (zh) * 2017-02-17 2018-10-01 印度商托仁特生技有限公司 具β-腎上腺素促效劑及抗蕈毒活性化合物
WO2019059953A2 (en) 2017-09-22 2019-03-28 Otitopic Inc. DRY POWDER COMPOSITIONS CONTAINING MAGNESIUM STEARATE
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
CN113544121A (zh) * 2019-06-06 2021-10-22 中国医药研究开发中心有限公司 具有β2受体激动及M受体拮抗活性的杂环衍生物及其医药用途
US20230322745A1 (en) * 2020-09-28 2023-10-12 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Fused tricyclic derivative and pharmaceutical application thereof
AU2023238504A1 (en) * 2022-03-25 2024-10-31 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystal of fused tricyclic derivative or pharmaceutically acceptable salt thereof

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1212742B (it) 1983-05-17 1989-11-30 Dompe Farmaceutici Spa Derivati dibenzo [1,4]diazepinonici pirido [1,4] benzodiazepinonici,pirido [1,5] benzodiazepinonici e loro attivita' farmacologica
EP0147475B1 (en) 1983-09-26 1987-03-18 MAGIS FARMACEUTICI S.p.A. Aminocyclohexanol derivatives having an expectorant activity, process for their preparation and pharmaceutical compositions containing them
EP1078629A3 (en) 1989-09-07 2001-05-23 Glaxo Group Limited Use of Salmeterol and salts for the treatment of inflammation and allergy
GB9020051D0 (en) 1990-09-13 1990-10-24 Pfizer Ltd Muscarinic receptor antagonists
WO1998009632A1 (en) 1996-09-06 1998-03-12 Merck & Co., Inc. Methods and compositions for treating preterm labor
SE9704644D0 (sv) 1997-12-12 1997-12-12 Astra Ab New use
US6673908B1 (en) 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
BR0013469B1 (pt) 1999-08-20 2011-01-25 amidas aromáticas heterocìclicas fungicidas, composição fungicida compreendendo as mesmas, bem como método para o controle ou a prevenção de infestação fúngica.
US6806314B2 (en) 2003-02-03 2004-10-19 Ppg Industries Ohio, Inc. Coating of Hydroxy-functional polymer(s), crosslinker, and 1,3- and 1,4-cyclohexane dimethanols
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
US7317102B2 (en) 2003-04-01 2008-01-08 Theravance, Inc. Diarylmethyl and related compounds
US7358244B2 (en) 2003-05-28 2008-04-15 Theravance, Inc. Azabicycloalkane compounds
US7320990B2 (en) 2004-02-13 2008-01-22 Theravance, Inc. Crystalline form of a biphenyl compound
DE102004024453A1 (de) 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
JP2008510014A (ja) 2004-08-16 2008-04-03 セラヴァンス, インコーポレーテッド β2アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
WO2006023460A2 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
NZ566068A (en) 2005-08-08 2011-03-31 Argenta Discovery Ltd Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
MEP9608A (en) 2006-03-20 2010-06-10 Pfizer Ltd Amine derivatives
GB0613154D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
WO2008017827A2 (en) 2006-08-08 2008-02-14 Argenta Discovery Limited Azole and thiazole derivatives and their uses
GB0702384D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd Chemical compounds
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
AP2009004791A0 (en) 2006-10-04 2009-04-30 Pfizer Ltd Sulfonamide derivatives as adrenergic agonists andmuscarinic antagonists
GB0700972D0 (en) 2007-01-18 2007-02-28 Imp Innovations Ltd Treatment of inflammatory disease
GB0702413D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New chemical compounds
WO2008096129A1 (en) 2007-02-07 2008-08-14 Argenta Discovery Ltd Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
WO2008149110A1 (en) 2007-06-08 2008-12-11 Argenta Discovery Limited Bicyclor [2.2.1] hept-7-ylamine derivatives and their use in the treatment of diseases and conditions in which m3 muscarinic receptor activity and beta-adrenergic activity are implicated
PE20090907A1 (es) 2007-07-21 2009-08-05 Boehringer Ingelheim Int Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
WO2009017813A1 (en) * 2007-08-02 2009-02-05 Teva Pharmaceutical Industries Ltd. O-desmethyl venlafaxine saccharinate
NZ586872A (en) 2008-02-06 2012-03-30 Astrazeneca Ab Spirocyclic amide compounds
CN101544572B (zh) 2008-03-26 2013-03-20 连云港恒邦医药科技有限公司 一种氨溴索衍生物及其制备方法
GB0808708D0 (en) 2008-05-13 2008-06-18 Astrazeneca Ab New compounds 274
MX2010013416A (es) * 2008-06-20 2010-12-21 Astrazeneca Ab Composicion farmaceutica que comprende un compuesto de 4-hidroxi-2-oxo-2,3-dihidro-1,3-benzotiazol-7-ilo para la modulacion de la actividad del adrenorreceptor beta 2.
US8263623B2 (en) 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
HRP20130468T1 (en) 2009-04-23 2013-06-30 Theravance, Inc. Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EP2426121A4 (en) 2009-04-30 2012-10-31 Teijin Pharma Ltd QUARTER AMMONIUM SALT CONNECTION
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
GB201002612D0 (en) * 2010-02-16 2010-03-31 Jagotec Ag Improvements in or relating to organic compounds
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
AR083115A1 (es) 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
EA022342B1 (ru) 2011-06-10 2015-12-30 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Соединения с активностью антагонистов мускариновых рецепторов и агонистов адренергического рецептора бета2
EP2718281B1 (en) 2011-06-10 2015-09-09 Chiesi Farmaceutici S.p.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
UA111867C2 (uk) 2011-11-11 2016-06-24 Аллерган, Інк. ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ І СПОСІБ ЗАСТОСУВАННЯ ПОХІДНИХ 4-ПРЕГНЕН-11β-17-21-ТРІОЛ-3,20-ДІОНУ
SG11201401531RA (en) 2011-11-11 2014-07-30 Pfizer 2-thiopyrimidinones
ES2912574T3 (es) 2011-11-11 2022-05-26 Gilead Apollo Llc Inhibidores de ACC y usos de los mismos
EP2592078A1 (en) * 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
HRP20180915T1 (hr) 2012-12-06 2018-07-27 Chiesi Farmaceutici S.P.A. Spojevi koji imaju aktivnost kao antagonist muskarinskog receptora i kao agonist beta2 adrenergijskog receptora
WO2014086927A1 (en) 2012-12-06 2014-06-12 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
AU2013360866A1 (en) 2012-12-18 2015-07-02 Almirall, S.A. New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activity
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201440768A (zh) 2013-02-27 2014-11-01 Almirall Sa 雙毒蕈鹼拮抗劑-β2腎上腺素促效劑複合物及皮質類固醇之組合物
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有maba化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β2腎上腺素受體促效劑二者之活性的2-胺基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β2腎上腺素促效劑及M3蕈毒拮抗劑活性之新穎雙環衍生物

Also Published As

Publication number Publication date
AU2014295028B2 (en) 2018-05-31
US20160166566A1 (en) 2016-06-16
MX2016000397A (es) 2016-04-29
NZ715128A (en) 2019-03-29
EA035436B1 (ru) 2020-06-15
HK1219043A1 (en) 2017-03-24
CY1122920T1 (el) 2021-10-29
KR20160034310A (ko) 2016-03-29
ZA201509203B (en) 2017-04-26
CR20160043A (es) 2016-04-08
PT3024489T (pt) 2020-05-05
RS60185B1 (sr) 2020-06-30
US9579316B2 (en) 2017-02-28
EA201600128A1 (ru) 2016-07-29
SMT202000185T1 (it) 2020-05-08
AR097079A1 (es) 2016-02-17
PH12016500125B1 (en) 2016-04-25
TWI641373B (zh) 2018-11-21
UY35678A (es) 2015-02-27
MY184681A (en) 2021-04-16
AU2014295028A1 (en) 2016-01-21
LT3024489T (lt) 2020-03-10
JP6374962B2 (ja) 2018-08-15
HRP20200670T1 (hr) 2020-07-10
PL3024489T3 (pl) 2020-08-10
SI3024489T1 (sl) 2020-04-30
MX360837B (es) 2018-11-20
IL243173B (en) 2019-10-31
BR112016001295A2 (enExample) 2017-07-25
JP2016525533A (ja) 2016-08-25
CN112321579A (zh) 2021-02-05
PH12016500125A1 (en) 2016-04-25
CL2016000187A1 (es) 2016-08-05
DK3024489T3 (da) 2020-05-04
CA2917596C (en) 2021-06-22
WO2015011244A1 (en) 2015-01-29
SG11201510682YA (en) 2016-02-26
IL243173A0 (en) 2016-02-29
KR102338155B1 (ko) 2021-12-10
TW201517907A (zh) 2015-05-16
NI201600012A (es) 2016-10-10
ES2788627T3 (es) 2020-10-22
CA2917596A1 (en) 2015-01-29
EP3024489B1 (en) 2020-02-19
BR112016001295B1 (pt) 2022-07-19
DOP2016000011A (es) 2016-06-15
EP3024489A1 (en) 2016-06-01
HUE049441T2 (hu) 2020-09-28
CN105492027A (zh) 2016-04-13

Similar Documents

Publication Publication Date Title
PE20160173A1 (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD ANTAGONISTA DE RECEPTORES MUSCARINICOS ASI COMO ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENERGICO
PE20151602A1 (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR B(beta)2 ADRENERGICO ASI COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARINICO M3
PE20141232A1 (es) Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos �2 y como antagonistas muscarinicos m3
CY1120258T1 (el) Ενωσεις ετεροδικυκλο-υποκατεστημενης-[1,2,4]τριαζολο [1,5-c]κιναζολιν-5-αμινης καταλληλες για αγωγη ή προληψη διαταραχων του κεντρικου νευρικου συστηματος
SA518391518B1 (ar) مشتقات n-] 2-(1- بنزيل ببريدين-4-يل) إيثيل[ -4-(بيرازين-2-يل)-ببرازين-1- كربوكساميد ومركبات متصلة بها كمضادات مستقبلة المسكارين 4 (m4) لمعالجة أمراض عصبية
PE20141231A1 (es) Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos �2 y como antagonistas muscarinicos m3
EA201591537A1 (ru) Производные бензотиофена и композиции, их содержащие, в качестве селективных супрессоров эстрогеновых рецепторов
PE20151001A1 (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
PE20091386A1 (es) Piperidino-dihidrotienopirimidinas sustituidas
AR047098A1 (es) Derivados de arilanilina como agonistas del receptor adrenergico beta2
CO6491058A2 (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
PE20141228A1 (es) Derivados de pirrolopirimidina y purina
AR060535A1 (es) Pirido-piridazinonas y ftalazinonas como antagonistas duales de los receptores h1 y h3 de histamina
PE20150774A1 (es) Aminoquinolinas como inhibidores de cinasa
PE20150399A1 (es) Nuevos derivados de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
CO2017000438A2 (es) Ácidos carboxílicos heterocíclicos como activadores de guanilato ciclasa soluble
DOP2013000243A (es) Inhibidores sustituidos de acetil-coa carboxilasa
PE20191528A1 (es) Nuevos derivados de triazolo[4,5-d]pirimidina
PE20141380A1 (es) Imidazopiridazinas como inhibidores de quinasa akt
HK1220386A1 (zh) Ep4受体拮抗剂在软骨疾病的治疗中的用途
PE20151060A1 (es) Nuevos derivados de pirazina como agonistas del receptor cb2
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa
AR067648A1 (es) Derivados de 2-aza-biciclo [2,2,2]octano, uso de los mismos y composiciones farmaceuticas que los contienen
PE20150629A1 (es) Derivados de etinilo como moduladores de la actividad del receptor de mglur5